文献速递临床微生物分子诊断质量管理与危急值

2018与2019年临床微生物学开放会议:新兴趋势、挑战与未来

Proceedings of the Clinical Microbiology Open 2018 and 2019 - a Discussion about Emerging Trends, Challenges, and the Future of Clinical Microbiology.
PubMed 文献 · J Clin Microbiol · 2022-05-31

本文汇总了由美国微生物学会临床与公共卫生微生物学委员会及企业理事会支持的临床微生物学开放会议(CMO)2018和2019年两届会议的讨论内容。会议聚焦创新技术的诊断潜力与实验室诊断管理,涵盖二代测序进入临床诊断、分子诊断改进、快速药敏与即时检验、人工智能利用大数据以及微生物实验室人员配置等议题。会后COVID-19大流行凸显了诊断微生物学界协同利用和扩展资源以应对疫情的必要性,会议讨论的问题与挑战在疫情应对中被证明至关重要。

要点

  • CMO会议为诊断微生物实验室、产业界与联邦机构提供互动平台,探讨当前与未来状态。
  • 讨论聚焦二代测序、分子诊断改进、快速药敏、即时检验和人工智能等创新技术。
  • 实验室诊断管理与人员配置是会议关注的关键挑战之一。

核心结论

  • CMO 2018和2019会议讨论的问题、挑战与潜在合作努力在诊断实验室、产业伙伴和联邦组织应对COVID-19中被证明至关重要。
  • 计划中的第三次CMO(2022)将从讨论型会议转变为行动型会议,主要聚焦反思COVID-19大流行经验并更好准备未来大流行。

研究设计与样本

  • CMO是由美国微生物学会临床与公共卫生微生物学委员会及企业理事会支持的会议,提供诊断微生物实验室、产业界与联邦机构领导者互动的平台。
  • 第一次和第二次CMO会议分别于2018年和2019年举行。

主要发现

  • 讨论聚焦创新技术的诊断潜力与实验室诊断管理。
  • 议题包括将二代测序扩展进入临床诊断、改进和推进分子诊断。
  • 议题包括新兴诊断,含快速抗菌药物敏感性试验和即时检验(POCT)。
  • 议题包括通过人工智能利用大数据以及临床微生物实验室人员配置。
  • CMO 2019后不久COVID-19大流行进一步凸显诊断微生物学界协同利用和扩展资源应对疫情的必要性。

临床怎么用

  • 诊断微生物实验室、产业界与联邦机构可通过此类平台协同应对诊断挑战并探索合作机会。
  • 应关注二代测序、分子诊断、快速药敏、POCT和人工智能等创新技术在临床微生物诊断中的应用。
  • 需重视实验室诊断管理与临床微生物实验室人员配置问题。
  • 应对未来大流行需诊断微生物学界协同利用和扩展资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical Microbiology Open (CMO), a meeting supported by the American Society for Microbiology's Clinical and Public Health Microbiology Committee (CPHMC) and Corporate Council, provides a unique interactive platform for leaders from diagnostic microbiology laboratories, industry, and federal agencies to discuss the current and future state of the clinical microbiology laboratory. The purpose is to leverage the group's diverse views and expertise to address critical challenges, and discuss potential collaborative opportunities for diagnostic microbiology, through the utilization of varied resources. The first and second CMO meetings were held in 2018 and 2019, respectively. Discussions were focused on the diagnostic potential of innovative technologies and laboratory diagnostic stewardship, including expansion of next-generation sequencing into clinical diagnostics, improvement and advancement of molecular diagnostics, emerging diagnostics, including rapid antimicrobial susceptibility and point of care testing (POCT), harnessing big data through artificial intelligence, and staffing in the clinical microbiology laboratory. Shortly after CMO 2019, the coronavirus disease 2019 (COVID-19) pandemic further highlighted the need for the diagnostic microbiology community to work together to utilize and expand on resources to respond to the pandemic. The issues, challenges, and potential collaborative efforts discussed during the past two CMO meetings proved critical in addressing the COVID-19 response by diagnostic laboratories, industry partners, and federal organizations. Planning for a third CMO (CMO 2022) is underway and will transition from a discussion-based meeting to an action-based meeting. The primary focus will be to reflect on the lessons learned from the COVID-19 pandemic and better prepare for future pandemics.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Doern CD, Miller MB, Alby K, et al. Proceedings of the Clinical Microbiology Open 2018 and 2019 - a Discussion about Emerging Trends, Challenges, and the Future of Clinical Microbiology. J Clin Microbiol. 2022. PMID: 35638361. doi:10.1128/jcm.00092-22

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。